BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 7 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2022. The put-call ratio across all filers is 3.11 and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $43,509,000 | +56.3% | 287,812 | +50.7% | 0.04% | +65.2% |
Q2 2022 | $27,835,000 | -65.7% | 191,031 | -72.1% | 0.02% | -58.9% |
Q1 2022 | $81,201,000 | +209.2% | 684,834 | +259.4% | 0.06% | +229.4% |
Q4 2021 | $26,261,000 | -32.2% | 190,559 | -31.6% | 0.02% | -37.0% |
Q3 2021 | $38,725,000 | +112.5% | 278,776 | +48.5% | 0.03% | +125.0% |
Q2 2021 | $18,224,000 | +43.3% | 187,725 | +0.9% | 0.01% | +33.3% |
Q1 2021 | $12,715,000 | -21.4% | 186,029 | -1.4% | 0.01% | -30.8% |
Q4 2020 | $16,170,000 | +39.7% | 188,658 | +5.9% | 0.01% | +30.0% |
Q3 2020 | $11,576,000 | +5.4% | 178,067 | +18.5% | 0.01% | 0.0% |
Q2 2020 | $10,985,000 | +325.9% | 150,256 | +98.3% | 0.01% | +233.3% |
Q1 2020 | $2,579,000 | +67.0% | 75,790 | +32.5% | 0.00% | +50.0% |
Q4 2017 | $1,544,000 | +12.3% | 57,216 | +55.6% | 0.00% | +100.0% |
Q3 2017 | $1,375,000 | -2.5% | 36,772 | -34.8% | 0.00% | 0.0% |
Q2 2017 | $1,410,000 | – | 56,390 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |